Saawan D. Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Saawan D. Patel has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
James N. Palmer
Department of Otorhinolaryngology University of Pennsylvania Philadelphia Pennsylvania USA
5 shared publications- Jennifer E. Douglas
Department of Otorhinolaryngology‐Head and Neck Surgery University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania USA
5 shared publications - Ariana L. Smith
Division of Urology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
4 shared publications Nithin D. Adappa
Department of Otorhinolaryngology University of Pennsylvania Philadelphia Pennsylvania USA
4 shared publicationsAlan D. Workman
Department of Otolaryngology Massachusetts Eye and Ear/Harvard Medical School Massachusetts Boston USA
3 shared publications- David K. Lerner
Department of Otolaryngology—Head and Neck Surgery University of Miami Miami Florida USA
3 shared publications
Latest Publications
- 1 November 2026
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 13 (6) , 578-579
Reply by Authors
- 1 November 2026
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 13 (6) , 578-579
Reply by Authors
- 1 November 2026
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 13 (6) , 569-579
Component-Level Cost and Variability Drivers of Intradetrusor OnabotulinumtoxinA Injections Across Office and Operating Room Settings
- 1 November 2026
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 13 (6) , 569-579
Component-Level Cost and Variability Drivers of Intradetrusor OnabotulinumtoxinA Injections Across Office and Operating Room Settings
- Open Access
- 5 October 2026
- Published by Wiley in Neurourology and Urodynamics
Predictors of 2‐Week Post‐Void Residual After Intradetrusor OnabotulinumtoxinA Injection for Overactive Bladder: A Sex‐ and Neurogenic Status‐Stratified Analysis
Objective: Urinary retention rates after intradetrusor onabotulinumtoxinA (BTX‐A) peak at 2 weeks, yet risk stratification by sex and neurogenic status remains limited. We evaluated predictors of 2‐week post‐void residual (PVR) and differences by sex and neurogenic bladder status using the largest retrospective cohort to date. Methods: We reviewed all BTX‐A procedures at a single academic institution from January 2020 to June 2025. Patients younger than 18 years, those with mean preprocedural PVR ≥ 150 mL, prior pelvic radiation, or preprocedural catheterization requirements were excluded. Two‐week PVR was analyzed using multivariable regression of demographics and urodynamic parameters, adjusting for total injections per patient, with subgroup analyses by sex‐assigned‐at‐birth and neurogenic status. Results: A total of 824 patients underwent 2282 BTX‐A injections. The cohort was predominantly female (95.9%) and non‐neurogenic (93.7%), with mean preprocedural PVR of 24 mL, mean BTX‐A dose of 120.8 units, and mean 2‐week PVR of 66.7 mL. Higher preprocedural PVR was associated with higher 2‐week PVR among female patients (β = 0.593 mL, 95% CI [0.303, 0.883]) and non‐neurogenic patients (β = 0.555, 95% CI [0.284, 0.825]), but not among male or neurogenic patients. Higher BTX‐A dose was similarly associated with higher 2‐week PVR among female patients (β = 25.7 mL per 100 U, 95% CI [6.16, 45.2]) and non‐neurogenic patients (β = 28.1 mL per 100U, 95% CI [10.5, 45.6]). Lower maximum flow rate (Qmax) was associated with higher 2‐week PVR among female patients (β = −1.25 mL per mL/sec, 95% CI [−1.94, −0.56]), neurogenic patients (β = −17.4, 95% CI [−31.5, −3.26]), and non‐neurogenic patients (β = −1.08, 95% CI [−1.74, −0.418]). Higher detrusor pressure at maximum flow (pDet@Qmax) was associated with higher 2‐week PVR among female (β = 0.557 mL/cmH 2 O, 95% CI 0.136, 0.979]) and neurogenic patients (β = 2.68 mL/cmH 2 O, 95% CI 0.126, 5.23]), whereas lower pDet@Qmax was associated with higher PVR among male patients (β = −8.34 mL/cmH 2 O, 95% CI −12.9, −3.76]). Conclusions: Pre‐procedural PVR and BTX‐A dose were consistent predictors of elevated 2‐week PVR in females and non‐neurogenic patients. These findings support sex‐ and neurogenic‐specific risk stratification and dose considerations prior to BTX‐A injection.
- 5 October 2026
- Published by Wiley in Neurourology and Urodynamics
Open AccessPredictors of 2‐Week Post‐Void Residual After Intradetrusor OnabotulinumtoxinA Injection for Overactive Bladder: A Sex‐ and Neurogenic Status‐Stratified Analysis
Objective: Urinary retention rates after intradetrusor onabotulinumtoxinA (BTX‐A) peak at 2 weeks, yet risk stratification by sex and neurogenic status remains limited. We evaluated predictors of 2‐week post‐void residual (PVR) and differences by sex and neurogenic bladder status using the largest retrospective cohort to date. Methods: We reviewed all BTX‐A procedures at a single academic institution from January 2020 to June 2025. Patients younger than 18 years, those with mean preprocedural PVR ≥ 150 mL, prior pelvic radiation, or preprocedural catheterization requirements were excluded. Two‐week PVR was analyzed using multivariable regression of demographics and urodynamic parameters, adjusting for total injections per patient, with subgroup analyses by sex‐assigned‐at‐birth and neurogenic status. Results: A total of 824 patients underwent 2282 BTX‐A injections. The cohort was predominantly female (95.9%) and non‐neurogenic (93.7%), with mean preprocedural PVR of 24 mL, mean BTX‐A dose of 120.8 units, and mean 2‐week PVR of 66.7 mL. Higher preprocedural PVR was associated with higher 2‐week PVR among female patients (β = 0.593 mL, 95% CI [0.303, 0.883]) and non‐neurogenic patients (β = 0.555, 95% CI [0.284, 0.825]), but not among male or neurogenic patients. Higher BTX‐A dose was similarly associated with higher 2‐week PVR among female patients (β = 25.7 mL per 100 U, 95% CI [6.16, 45.2]) and non‐neurogenic patients (β = 28.1 mL per 100U, 95% CI [10.5, 45.6]). Lower maximum flow rate (Qmax) was associated with higher 2‐week PVR among female patients (β = −1.25 mL per mL/sec, 95% CI [−1.94, −0.56]), neurogenic patients (β = −17.4, 95% CI [−31.5, −3.26]), and non‐neurogenic patients (β = −1.08, 95% CI [−1.74, −0.418]). Higher detrusor pressure at maximum flow (pDet@Qmax) was associated with higher 2‐week PVR among female (β = 0.557 mL/cmH 2 O, 95% CI 0.136, 0.979]) and neurogenic patients (β = 2.68 mL/cmH 2 O, 95% CI 0.126, 5.23]), whereas lower pDet@Qmax was associated with higher PVR among male patients (β = −8.34 mL/cmH 2 O, 95% CI −12.9, −3.76]). Conclusions: Pre‐procedural PVR and BTX‐A dose were consistent predictors of elevated 2‐week PVR in females and non‐neurogenic patients. These findings support sex‐ and neurogenic‐specific risk stratification and dose considerations prior to BTX‐A injection.
- 9 July 2026
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 16 (9) , 1031-1033
The Utilization of the Completeness of Surgery Index in Revision Endoscopic Sinus Surgery Patients on Biologic Therapy for CRSwNP
Key Points: Revision surgery in patients on biologic therapy with lower preoperative CoSI scores (<70, reflecting previously incomplete surgery) resulted in significantly greater improvement in SNOT‐22 after revision surgery compared to patients with previously adequate surgery. Incomplete prior surgery, as assessed by the CoSI, remains a likely correctable contributor to symptomatology even in patients receiving biologics.
- 9 July 2026
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 16 (9) , 1031-1033
The Utilization of the Completeness of Surgery Index in Revision Endoscopic Sinus Surgery Patients on Biologic Therapy for CRSwNP
Key Points: Revision surgery in patients on biologic therapy with lower preoperative CoSI scores (<70, reflecting previously incomplete surgery) resulted in significantly greater improvement in SNOT‐22 after revision surgery compared to patients with previously adequate surgery. Incomplete prior surgery, as assessed by the CoSI, remains a likely correctable contributor to symptomatology even in patients receiving biologics.
- Open Access
- 10 November 2025
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 15 (12) , 1433-1435
Post‐Operative Surveillance After Resection of Uncommon Benign Sinonasal Tumors: A Multi‐Institutional Review
- 10 November 2025
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 15 (12) , 1433-1435
Open AccessPost‐Operative Surveillance After Resection of Uncommon Benign Sinonasal Tumors: A Multi‐Institutional Review
- Open Access
- 4 September 2025
- Published by Elsevier in Ophthalmology Science
- Vol. 6 (1) , 100935
Autonomous Artificial Intelligence in Diabetic Retinopathy Testing—Lessons Learned on Successful Health System Adoption
- 4 September 2025
- Published by Elsevier in Ophthalmology Science
- Vol. 6 (1) , 100935
Open AccessAutonomous Artificial Intelligence in Diabetic Retinopathy Testing—Lessons Learned on Successful Health System Adoption
- Open Access
- 30 December 2024
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 15 (4) , 441-444
Outcomes of Autologous versus Synthetic Inlay Grafts After Skull Base Reconstruction for High‐Flow Defects: A Multicenter Case‐Control Analysis
- 30 December 2024
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 15 (4) , 441-444
Open AccessOutcomes of Autologous versus Synthetic Inlay Grafts After Skull Base Reconstruction for High‐Flow Defects: A Multicenter Case‐Control Analysis
- Open Access
- 3 December 2024
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 15 (4) , 384-394
Comparison of surveillance modalities in the surveillance of sinonasal squamous cell carcinoma recurrence: A multi‐institutional study
Background: Recurrence of sinonasal squamous cell carcinoma (SNSCC) follows an aggressive course, and early detection is paramount. This study identifies the parameters of different surveillance modalities.Methods: We conducted a retrospective study of 105 SNSCC patients at three academic institutions from November 2009 to July 2024. Patient records were reviewed for demographics, tumor characteristics, endoscopy, CT, PET/CT, and MRI findings. Multivariable analyses were performed in RStudio.Results: Mean time to recurrence was 12.1 months (SD 13.9 months). Patients with higher Charlson Comorbidity Index (p = 0.041), endoscopic surgical approach (p = 0.015), and suspicious surveillance findings (p = 0.029) had higher rates of recurrence. Endoscopy showed a sensitivity of 18.5% and specificity of 99.2%, with a positive predictive value (PPV) of 45.5% and negative predictive value (NPV) of 97.0%. CT had a sensitivity of 75.0% and specificity of 100.0%, with a PPV of 100.0% and NPV of 97.6%. PET/CT demonstrated a sensitivity of 95.2% and specificity of 90.8%, with a PPV of 64.5% and NPV of 97.6%. MRI showed a sensitivity of 72.4% and specificity of 97.1%, with a PPV of 65.6% and NPV of 97.9%. The median time from the last normal surveillance to recurrence was 2.07 months for endoscopy, 8.61 months for CT, 8.15 months for PET/CT, and 6.49 months for MRI.Conclusions: The high specificity and NPV of endoscopy, alongside the high sensitivity of PET/CT, support a multimodal approach for surveillance. Given the mean onset of SNSCC recurrence at 12.1 months, surveillance beyond the National Comprehensive Cancer Network's asymptomatic 6‐month guideline is warranted, and follow‐up should be tailored to patient‐specific risk factors.
- 3 December 2024
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 15 (4) , 384-394
Open AccessComparison of surveillance modalities in the surveillance of sinonasal squamous cell carcinoma recurrence: A multi‐institutional study
Background: Recurrence of sinonasal squamous cell carcinoma (SNSCC) follows an aggressive course, and early detection is paramount. This study identifies the parameters of different surveillance modalities.Methods: We conducted a retrospective study of 105 SNSCC patients at three academic institutions from November 2009 to July 2024. Patient records were reviewed for demographics, tumor characteristics, endoscopy, CT, PET/CT, and MRI findings. Multivariable analyses were performed in RStudio.Results: Mean time to recurrence was 12.1 months (SD 13.9 months). Patients with higher Charlson Comorbidity Index (p = 0.041), endoscopic surgical approach (p = 0.015), and suspicious surveillance findings (p = 0.029) had higher rates of recurrence. Endoscopy showed a sensitivity of 18.5% and specificity of 99.2%, with a positive predictive value (PPV) of 45.5% and negative predictive value (NPV) of 97.0%. CT had a sensitivity of 75.0% and specificity of 100.0%, with a PPV of 100.0% and NPV of 97.6%. PET/CT demonstrated a sensitivity of 95.2% and specificity of 90.8%, with a PPV of 64.5% and NPV of 97.6%. MRI showed a sensitivity of 72.4% and specificity of 97.1%, with a PPV of 65.6% and NPV of 97.9%. The median time from the last normal surveillance to recurrence was 2.07 months for endoscopy, 8.61 months for CT, 8.15 months for PET/CT, and 6.49 months for MRI.Conclusions: The high specificity and NPV of endoscopy, alongside the high sensitivity of PET/CT, support a multimodal approach for surveillance. Given the mean onset of SNSCC recurrence at 12.1 months, surveillance beyond the National Comprehensive Cancer Network's asymptomatic 6‐month guideline is warranted, and follow‐up should be tailored to patient‐specific risk factors.
- Open Access
- 26 September 2024
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 15 (2) , 120-127
Time is money: An analysis of cost drivers in ambulatory sinus surgery
Background: Functional endoscopic sinus surgery (FESS) is one of the most commonly performed otolaryngologic procedures and is associated with significant cost variability.Methods: We performed a retrospective analysis of all inflammatory sinus surgeries at a single tertiary care medical center from July 2021 to July 2023. The electronic medical record was reviewed for patient factors and cost variables for each procedure, and multivariable analysis was performed.Results: A total of 221 patients were included in analysis with a mean age of 48.2 years. There was a 44.8% incidence (n = 99) of nasal polyps and 31.2% (n = 69) of cases were revision surgeries. The average total cost for the surgical encounter was $8960.31 (standard deviation $1967.97). Operating room time represented $4912.46 (54.8% of all costs), while average operating room supply costs were $1296.06 (14.5%) and recovery room costs were $919.48 (10.3%). Total costs were significantly associated with length of surgery ($7.83/min, p = 0.04), in addition to presence of nasal polyps ($531.96, p = 0.04). There was no significant association between total costs and the remaining clinical and demographic factors.Conclusions: Costs associated with ambulatory FESS for inflammatory sinus disease vary across patients and this cost variability is predominantly driven by time efficiency within the operating room, as well as supply utilization and nasal polyposis to a lesser degree. As a result, operating room efficiency represents a primary target for cost‐related interventions. Additionally, our data provide a framework for surgeons and hospitals to make evidence‐based decisions on intraoperative equipment in a tradeoff between efficiency and supply costs. Our findings indicate that an approach focused on streamlining efficiency across the entire ambulatory surgery encounter will have the greatest impact on reducing healthcare expenses for both the patient and the health system.
- 26 September 2024
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 15 (2) , 120-127
Open AccessTime is money: An analysis of cost drivers in ambulatory sinus surgery
Background: Functional endoscopic sinus surgery (FESS) is one of the most commonly performed otolaryngologic procedures and is associated with significant cost variability.Methods: We performed a retrospective analysis of all inflammatory sinus surgeries at a single tertiary care medical center from July 2021 to July 2023. The electronic medical record was reviewed for patient factors and cost variables for each procedure, and multivariable analysis was performed.Results: A total of 221 patients were included in analysis with a mean age of 48.2 years. There was a 44.8% incidence (n = 99) of nasal polyps and 31.2% (n = 69) of cases were revision surgeries. The average total cost for the surgical encounter was $8960.31 (standard deviation $1967.97). Operating room time represented $4912.46 (54.8% of all costs), while average operating room supply costs were $1296.06 (14.5%) and recovery room costs were $919.48 (10.3%). Total costs were significantly associated with length of surgery ($7.83/min, p = 0.04), in addition to presence of nasal polyps ($531.96, p = 0.04). There was no significant association between total costs and the remaining clinical and demographic factors.Conclusions: Costs associated with ambulatory FESS for inflammatory sinus disease vary across patients and this cost variability is predominantly driven by time efficiency within the operating room, as well as supply utilization and nasal polyposis to a lesser degree. As a result, operating room efficiency represents a primary target for cost‐related interventions. Additionally, our data provide a framework for surgeons and hospitals to make evidence‐based decisions on intraoperative equipment in a tradeoff between efficiency and supply costs. Our findings indicate that an approach focused on streamlining efficiency across the entire ambulatory surgery encounter will have the greatest impact on reducing healthcare expenses for both the patient and the health system.
- Open Access
- 3 September 2024
- Published by Elsevier in Urology Case Reports
- Vol. 57, 102834
Transrectal bladder prolapse in a male managed with a robotic-assisted laparoscopic cystoprostosacropexy
- 3 September 2024
- Published by Elsevier in Urology Case Reports
- Vol. 57, 102834
Open AccessTransrectal bladder prolapse in a male managed with a robotic-assisted laparoscopic cystoprostosacropexy